Environmental Laboratory
Sweden calls for tighter EU environmental legislation
Jul 12 2011
Many new medicines that find their way on to the European market are produced in countries such as India.
The MPA is concerned about the potential damage that could be caused to human health if companies do not take environmental health more seriously.
A report published by the organisation stated that emissions from such manufacturing plants are unacceptable and improvements are "an urgent matter".
Members of the MPA want the EU to sanction rulings that force Indian firms to better control the production of certain products - particularly those that have been proven to have an adverse affect on human and animal wellbeing.
"First and foremost this concerns antibiotics, certain medicinal products with hormone-disrupting substances and substances that can constitute a risk to the environment [if] they are used and produced in large volumes," the report read.
Around 600 pharmacists and doctors work at the MPA, which is a government body and one of the EU's leading regulatory authorities.
Posted by Lauren Steadman
Digital Edition
AET 28.4 Oct/Nov 2024
November 2024
Gas Detection - Go from lagging to leading: why investment in gas detection makes sense Air Monitoring - Swirl and vortex meters will aid green hydrogen production - Beyond the Stack: Emi...
View all digital editions
Events
Dec 02 2024 London, UK
Dec 03 2024 Dusseldorf, Germany
Dec 11 2024 Shanghai, China
Jan 12 2025 Abu Dhabi, UAE
Jan 14 2025 Abu Dhabi, UAE